Tetrabenazine News and Research

RSS
Tetrabenazine is a highly selective and reversible centrally-acting dopamine depleting drug that works by inhibiting a molecule known as vesicular monoamine transporter 2 (VMAT2). Xenazine was approved by the FDA on August 15, 2008, for the treatment of chorea associated with Huntington's disease, based on the results of a double-blind, placebo-controlled, Phase 3 study that found Xenazine significantly reduced patients' chorea burden, improved global outcome scores, and was generally safe and well tolerated. Additional post-marketing preclinical studies further elucidating the safety profile of the product are being conducted. Tetrabenazine has been available in Europe for more than 30 years and in Canada since 1996.
FDA approves tetrabenazine for Huntington's disease

FDA approves tetrabenazine for Huntington's disease

Tetrabenazine protects brain cells in Huntington's disease model

Tetrabenazine protects brain cells in Huntington's disease model

Tetrabenazine cuts down involuntary movements in Huntington's disease

Tetrabenazine cuts down involuntary movements in Huntington's disease

Botox may be a possible treatment for sufferers of Tourette's syndrome

Botox may be a possible treatment for sufferers of Tourette's syndrome